Key Highlights
- Second-quarter revenue reached $15.38 billion, representing a 5% increase on a constant currency basis
- Core earnings per share jumped 18% to $2.63, surpassing Wall Street’s $2.48 projection
- Cancer treatment division posted 15% growth at constant currency, compensating for weakness elsewhere
- Company reaffirmed its ambitious $80 billion revenue goal for 2030
- Ultomiris late-stage trial missed primary endpoint; Wainua study also fell short earlier in the month
Shares of AstraZeneca climbed approximately 1.6% during early Monday trading sessions following the pharmaceutical giant’s announcement of second-quarter financial results that exceeded market projections.
Revenue for the three-month period totaled $15.38 billion, marking an increase from $14.46 billion recorded during the corresponding quarter of the previous year. This translates to a 5% gain when adjusted for constant currency fluctuations. Wall Street analysts had projected $15.39 billion, placing the actual figure virtually on target.
The profit metric delivered the more impressive performance. Core earnings per share registered at $2.63, climbing 18% on a constant currency basis, well above the Street consensus forecast of $2.48. Net income advanced to $2.51 billion compared to $2.45 billion in the year-ago period.
The oncology portfolio served as the primary growth driver for the quarter. Cancer drug revenue expanded 15% at constant currency, compensating for softness across the cardiovascular, renal and metabolism, and infectious disease segments, all of which experienced declines.
Clinical Trial Challenges Under Investor Spotlight
AstraZeneca’s clinical development program has faced increasing investor attention in recent weeks. Earlier in the month, a pivotal study evaluating Wainua for a cardiac indication failed to achieve its primary endpoint, pressuring share prices.
Over the weekend, the pharmaceutical company announced another clinical disappointment. A trial assessing Ultomiris, its rare-disease therapy, did not meet its primary objective in patients suffering from a serious stem-cell transplant complication.
On a brighter note, the company simultaneously reported positive outcomes from a late-stage trial in gastric cancer treatment.
Chief Executive Pascal Soriot sought to address investor concerns. “We remain confident in the strength of our pipeline and have more than twenty high-value readouts due over the next 18 months,” he stated.
Long-Term Revenue Projection Unchanged
Notwithstanding the recent clinical setbacks, AstraZeneca maintained its forward-looking projections. The pharmaceutical company continues to anticipate 2026 core earnings per share will expand by a low double-digit percentage on a constant currency basis, while total revenue is expected to increase at a mid-to-high single-digit pace.
The ambitious $80 billion annual revenue objective for 2030, established in 2024, was also confirmed. JPMorgan research analysts indicated Monday they continue to view the company as capable of achieving that milestone.
AZN shares have increased more than fourfold since Soriot assumed leadership 14 years ago. However, the stock has declined approximately 8% year-to-date in 2026, underperforming competitor GSK.
Two upcoming late-stage clinical trial results expected in the coming months are drawing significant attention as investors evaluate the durability of the development pipeline.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
